ScoreComparison
Why is Immunome, Inc. ?
1
Flat results in Mar 26
- OPERATING CASH FLOW(Y) Lowest at USD -196.5 MM
- NET PROFIT(9M) At USD -171.2 MM has Grown at -26.9%
- RAW MATERIAL COST(Y) Grown by 101.35% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 112.23%, its profits have risen by 21.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Immunome, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Immunome, Inc.
112.23%
0.23
71.96%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
51.34%
EBIT Growth (5y)
-272.93%
EBIT to Interest (avg)
-150.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.20
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.50
EV to EBIT
-7.31
EV to EBITDA
-7.41
EV to Capital Employed
-81.77
EV to Sales
225.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-31.91%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
NET PROFIT(HY)
Higher at USD -113.74 MM
ROCE(HY)
Highest at -50.14%
CASH AND EQV(HY)
Highest at USD 1,236.17 MM
EPS(Q)
Highest at USD -0.48
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -196.5 MM
NET PROFIT(9M)
At USD -171.2 MM has Grown at -26.9%
RAW MATERIAL COST(Y)
Grown by 101.35% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at -98.35 %
Here's what is working for Immunome, Inc.
Net Profit
Higher at USD -113.74 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.48
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 1,236.17 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Immunome, Inc.
Operating Cash Flow
Lowest at USD -196.5 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -98.35 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 101.35% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
